ClinicalTrials.gg
Active, not recruitingNCT05180799Updated Jun 15, 2025

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

A Phase 1/2 interventional study of BA3071 and Nivolumab in NSCLC and Melanoma, sponsored by BioAtla, Inc.. Active, not recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by BioAtla, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 12 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
320
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,050 studies in Melanoma with a site in United States — 242 open to participants now, 437 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
154th of 1,750
320 · median 37
Started
2022
with 87 others
Phase 1/2
286 of 2,050
48 open now
Primary completion
2025-03
later than 55 of 432 live
Registered
1,717th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 154th largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 88 that started in 2022, is one of 286 in phase 1/2, reaches primary completion later than 55 of the 432 other live ones, and was the 1,717th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

242 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Read the detailed description

This is a multi-center, open-label study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3071. Phase 2 is open and currently recruiting patients with:

  1. Melanoma - 1L
  2. nonsquamous or recurrent NSCLC (Type IIB, IIIA, IV) with single or any combination of the following mutations: KRAS mutation STK11 mutation KEAP1 mutation PD-L1 tumor proportion score (TPS) \<1%
03

Conditions studied

  • NSCLC
  • Melanoma

Keywords

  • metastatic
  • cancer
  • First Line Melanoma
  • First Line NSCLC; 1L NSCLC
  • Treatment Refractory Melanomas
  • Nonsquamous Stage IV
  • Nonsquamous recurrent
  • 1L NSCLC
  • Systemic Treatment Naive
  • Nonsquamous Stage IIB
  • Nonsquamous Stage IIIA
  • KRAS
  • STK11
  • KEAP1
  • PD-L1 tumor proportion score (TPS) <1%
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have .
  • Age ≥ 18 years
  • CLTA-4 blocking-antibody naïve
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an (ECOG) performance status of 0 or 1.
  • Patients must have single or any combination of the following mutations: KRAS, STK11, KEAP1 and/or TPS \<1%
  • Patients must be eligible for surgery (NSCLC Stage IIB-IIIA only)

Exclusion criteria

Exclusion Criteria:

  • Patients must not have cardiac disease.
  • Patients must not have known non-controlled .
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3071 administration.
  • Patients must not have known (HIV) infection, active and/or .
  • Patients must not be women who are pregnant or breast feeding.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    BA3071

    Conditionally active biologic (CAB) antibody that binds to CTLA-4

    Biological: BA3071

  • Experimental
    Combination Therapy

    Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor

    Biological: BA3071 · Biological: Nivolumab · Biological: Pembrolizumab

  • Experimental
    Combination Therapy + Chemotherapy

    Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy

    Biological: BA3071 · Biological: Pembrolizumab · Drug: Pemetrexed (Alimta)

  • Experimental
    Neoadjuvant Combination Therapy + Chemotherapy

    Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor + Chemotherapy prior to surgical resection

    Biological: BA3071 · Biological: Pembrolizumab · Drug: Pemetrexed (Alimta)

Interventions

  • BiologicalBA3071

    Conditionally active biologic (CAB) antibody that binds to CTLA-4

  • BiologicalNivolumab

    Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1

  • BiologicalPembrolizumab

    Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor

  • DrugPemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    pemetrexed with either cisplatin or carboplatin

06

What researchers measure

Primary outcomes

  1. Assess dose limiting toxicity as defined in the protocol

    Phase 1: Safety Profile

    Time frame: Up to 24 months

  2. Assess maximum tolerated dose as defined in the protocol

    Phase 1: Safety Profile

    Time frame: Up to 24 months

  3. Frequency and severity of AEs and/or SAEs

    Phase 1 and 2: Safety Profile

    Time frame: Up to 24 months

  4. Confirmed overall response rate (ORR) per RECIST v1.1

    Phase 2: Efficacy

    Time frame: Up to 24 months

Secondary outcomes

  1. Phase 1: Pharmacokinetics

    Plasma concentrations of ADC

    Time frame: Up to 24 months

  2. Phase 1: Pharmacokinetics

    Plasma concentrations of total antibody

    Time frame: Up to 24 months

  3. Phase 1: Pharmacokinetics

    Plasma concentrations of MMAE

    Time frame: Up to 24 months

  4. Peak Plasma Concentration (Cmax)

    Phase 1: Pharmacokinetics

    Time frame: Up to 24 months

  5. Area under the plasma concentration versus time curve (AUC)

    Phase 1: Pharmacokinetics

    Time frame: Up to 24 months

  6. Confirmed best overall response (BOR)

    Phase 1 and 2: Efficacy

    Time frame: Up to 24 months

  7. Confirmed overall response rate (ORR)

    Phase 2: Efficacy

    Time frame: Up to 24 months

  8. Disease control rate (DCR)

    Phase 1 and 2: Efficacy

    Time frame: Up to 24 months

  9. Time to response (TTR)

    Phase 1 and 2: Efficacy

    Time frame: Up to 24 months

  10. Overall survival (OS)

    Phase 1 and 2: Efficacy

    Time frame: Up to 24 months

  11. Percent change from baseline in target lesion sum of diameters.

    Phase 1 and 2: Efficacy

    Time frame: Up to 24 months

  12. Duration of response (DOR)

    Phase 1 and 2: Efficacy

    Time frame: Up to 24 months

  13. Progression-free survival (PFS)

    Phase 1 and 2: Efficacy

    Time frame: Up to 24 months

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2025, 31 months.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 84. This study's 31 months is below that.

Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2021
First posted
Jan 6, 2022
StartActual
Aug 3, 2022
Primary completionActual
Mar 19, 2025
CompletionEst.
Jun 30, 2026
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05180799
Lead sponsor
BioAtla, Inc.
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Aug 3, 2022
Primary completion
Mar 19, 2025
Completion
Jun 30, 2026 (estimated)
Last update
Jun 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion